Liberate-H2H

Liberate-H2H

The study is designed to evaluate the efficacy and safety of LIB003 compared to Evolocumab and Alirocumab in patients with or at high risk for cardiovascular disease, on stable lipid-lowering therapy who require additional LDL reduction.

Please use this link for further information:

Primary Investigator: Odayme Quesada